High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

If you live in the United States, you’ve likely seen drug commercials like this one: “If you’re living with moderate to severe plaque psoriasis or active psoriatic arthritis, symptoms can sometimes ...

Additionally, AbbVie is an exceptional income stock. It's a Dividend King, with 52 consecutive years of payout increases including the time it spent under the wing of its former parent company, Abbott ...

Sales of Skyrizi and Rinvoq grew by 50% and 45%, respectively -- much faster than any other medicine in the company's portfolio, even though they generate the highest sales aside from Humira.

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine rivals ... AbbVie’s Skyrizi, Gilead Sciences' Biktarvy and J&J’s ...

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and ...

and AbbVie’s recently-approved Skyrizi (risankizumab) – are already shifting treatment away from older TNF blockers. That is down to higher skin clearance rates and also because they don’t ...

The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to ... plastics and regenerative medicine, body contouring, ...